An estimated 9.5 million people were living with type 1 diabetes worldwide in 2025, with approximately 500,000 new diagnoses recorded that year.

SWITZERLAND—The World Health Organization (WHO) has issued its first guidelines for diagnosing and managing type 1 diabetes in adults to improve access to essential treatment across healthcare settings, including low-resource and humanitarian environments.
More than a century after insulin was discovered, millions of people with type 1 diabetes still struggle to access affordable insulin and essential medical care.
The lifelong condition occurs when the pancreas produces little or no insulin, making daily insulin treatment necessary for survival.
Growing burden among adults
An estimated 9.5 million people were living with type 1 diabetes worldwide in 2025, with approximately 500,000 new diagnoses recorded that year.
Although the condition is commonly associated with childhood, adults also account for a growing share of cases.
“Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said Dr Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health.
He noted that the new guidelines provide evidence-based recommendations to help countries improve diabetes care, particularly where healthcare resources are limited or services have been disrupted.
WHO outlines treatment and monitoring standards
The guidelines recommend multiple daily insulin injections, with doses adjusted according to blood glucose levels.
Human insulin, which works similarly to the insulin naturally produced by the body, remains an effective treatment option.
Other insulin formulations may also be used where clinically appropriate.
WHO also recommends regular blood glucose monitoring to support treatment decisions and reduce the risk of complications.
Healthcare facilities can assess long-term glucose control through tests that measure average blood sugar levels over several months.
For daily monitoring, patients can use finger-prick blood tests or continuous glucose monitoring devices, which measure glucose levels through sensors worn on the skin.
Where blood glucose testing is unavailable, urine glucose testing may serve as an alternative.
Implications for healthcare systems
Issued ahead of World Diabetes Day on November 14, 2026, the recommendations support WHO’s 2030 targets to ensure that everyone living with type 1 diabetes can access affordable insulin and self-monitoring of blood glucose.
They also provide a framework for countries to strengthen diabetes services, improve access to essential medical supplies and address gaps in care across different healthcare settings.
WHO plans to support implementation by providing practical tools and guidance to help countries monitor progress.
It also encourages governments to involve people living with type 1 diabetes in designing, implementing and evaluating national diabetes programmes.
The 2026 World Diabetes Day theme, Early action on diabetes, highlights the importance of timely diagnosis and treatment.
Diabetes can cause serious complications, including blindness, kidney failure, heart attacks, strokes and lower-limb amputations.
Globally, the number of people living with diabetes has more than quadrupled since 1990.
WHO estimated that 830 million people had diabetes in 2022, most of them living with type 2 diabetes.
More than 40% of people with diabetes remain unaware of their condition and therefore have not received a diagnosis.
Be the first to leave a comment